Literature DB >> 28002114

Treatment of Pseudomonas Keratitis by Continuous Infusion of Topical Antibiotics With the Morgan Lens.

Mingwu Wang1, Whitney A Smith, Joshua K Duncan, Joseph M Miller.   

Abstract

PURPOSE: Despite following standard treatment, Pseudomonas keratitis can continue to progress and result in loss of vision or of the eye. Our cases demonstrate that the Morgan Lens can be an effective topical antibiotic delivery vehicle in advanced keratitis.
METHODS: Two patients (3 eyes) with Pseudomonas keratitis were included in this report after failing to respond to intense inpatient topical treatment. Because loss of the eyes was imminent, the Morgan Lenses were used for continuous lavage with ceftazidime (50 mg/mL), in conjunction with other conventional treatment.
RESULTS: Three days after lavage, corneal cultures became negative in all eyes. Infusion was continued for at least a week to ensure sterilization of the infection before switching to standard topical therapy. The infection in both cases was promptly eradicated and the eyes were rescued.
CONCLUSIONS: The Morgan Lens can be a viable alternative in treating severe and aggressive infectious keratitis or sclerokeratitis. Application of the Morgan Lens is noninvasive and requires minimal training. Intravenous tubing connectors allow for easy swapping between medications, simultaneous administration of multiple medications, and titration of dosing. Additionally, it is cost-effective as the low demand for nursing care essentially eliminates the need for intensive care unit admission.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28002114     DOI: 10.1097/ICO.0000000000001128

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Recalcitrant Pseudomonas Aeruginosa Keratitis with Hyphaema.

Authors:  Amy Chan; Hnin Hnin Oo; Philip Stanley; Benjamin Chang
Journal:  Case Rep Ophthalmol       Date:  2021-04-12

2.  Treatment of Severe Acute Bacterial Keratitis in Rabbits Using Continuous Topical Ocular Instillation with Norvancomycin.

Authors:  Wenxiang Lin; Libei Zhao; Qian Tan; Ding Lin
Journal:  Drug Des Devel Ther       Date:  2021-02-16       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.